Additionally, the 36-month beta value for MNOV is 0.76. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MNOV is 46.48M and currently, short sellers hold a 0.39% ratio of that float. The average trading volume of MNOV on November 13, 2024 was 39.29K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MNOV) stock’s latest price update
The stock price of Medicinova Inc (NASDAQ: MNOV) has jumped by 49.02 compared to previous close of 1.53. Despite this, the company has seen a gain of 41.61% in its stock price over the last five trading days. globenewswire.com reported 2024-11-11 that LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through this settlement. Further details will be provided as they become available.
MNOV’s Market Performance
Medicinova Inc (MNOV) has seen a 41.61% rise in stock performance for the week, with a 28.81% gain in the past month and a 100.00% surge in the past quarter. The volatility ratio for the week is 14.96%, and the volatility levels for the past 30 days are at 7.88% for MNOV. The simple moving average for the past 20 days is 32.56% for MNOV’s stock, with a 53.93% simple moving average for the past 200 days.
Analysts’ Opinion of MNOV
Many brokerage firms have already submitted their reports for MNOV stocks, with Maxim Group repeating the rating for MNOV by listing it as a “Buy.” The predicted price for MNOV in the upcoming period, according to Maxim Group is $15 based on the research report published on March 10, 2021 of the previous year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see MNOV reach a price target of $22. The rating they have provided for MNOV stocks is “Buy” according to the report published on March 25th, 2019.
B. Riley FBR Inc. gave a rating of “Buy” to MNOV, setting the target price at $22 in the report published on March 28th of the previous year.
MNOV Trading at 24.74% from the 50-Day Moving Average
After a stumble in the market that brought MNOV to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 5.56% of gains for the given period.
Volatility was left at 7.88%, however, over the last 30 days, the volatility rate increased by 14.96%, as shares surge +25.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.18% upper at present.
During the last 5 trading sessions, MNOV rose by +41.61%, which changed the moving average for the period of 200-days by +57.24% in comparison to the 20-day moving average, which settled at $1.7200. In addition, Medicinova Inc saw 52.00% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MNOV
Current profitability levels for the company are sitting at:
- -5093.0 for the present operating margin
- 0.9 for the gross margin
The net margin for Medicinova Inc stands at -35.99. The total capital return value is set at -19.95. Equity return is now at value -13.32, with -12.65 for asset returns.
Based on Medicinova Inc (MNOV), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -44.99. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -25264.23.
Currently, EBITDA for the company is -9.88 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 299.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.24.
Conclusion
In conclusion, Medicinova Inc (MNOV) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
